Last reviewed · How we verify

NCT05637892

A Cohort Study of Hydatidiform Mole

Not yet recruiting Last updated 8 December 2022
What this trial tests

trial testing No intervention in Hydatidiform Mole in 800 participants. Not yet recruiting.

Timeline
1 December 2022
Primary endpoint
1 December 2026
1 June 2027

Quick facts

Lead sponsorWomen's Hospital School Of Medicine Zhejiang University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment800
Start date1 December 2022
Primary completion1 December 2026
Estimated completion1 June 2027

Drugs / interventions tested

Conditions studied

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 13 to 55, female only, with Hydatidiform Mole. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to construct a cohort for the hydatidiform mole.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Hydatidiform Mole

Currently open trials in the same condition.

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05637892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing